tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Neuren Pharmaceuticals Limited (NURPF)
OTHER OTC:NURPF
US Market
NURPF
Neuren Pharmaceuticals Limited
RESEARCH TOOLSreports

Neuren Pharmaceuticals Limited (NURPF) Stock News & Sentiment

Compare
54 Followers
Neuren’s Partner Acadia Sees DAYBUE Sales Climbing to US$700m by 2028
Premium
Company Announcements
Neuren’s Partner Acadia Sees DAYBUE Sales Climbing to US$700m by 2028
5d ago
Neuren’s Phase 3 NNZ-2591 Trial Targets a High-Value Niche in Phelan-McDermid Syndrome
Premium
Company Announcements
Neuren’s Phase 3 NNZ-2591 Trial Targets a High-Value Niche in Phelan-McDermid Syndrome
11d ago
NURPF
Neuren Advances NNZ-2591 Program as Phase 2 PMS Data Published and Phase 3 Koala Trial Recruits in US
Premium
Company Announcements
Neuren Advances NNZ-2591 Program as Phase 2 PMS Data Published and Phase 3 Koala Trial Recruits in US
12d ago
Neuren Wins Health Canada Nod to Expand Phase 3 Trial of NNZ-2591 in Phelan-McDermid Syndrome
Premium
Company Announcements
Neuren Wins Health Canada Nod to Expand Phase 3 Trial of NNZ-2591 in Phelan-McDermid Syndrome
28d ago
Neuren Pharmaceuticals’ Partner Acadia Gains FDA Approval for New Rett Syndrome Treatment
Premium
Company Announcements
Neuren Pharmaceuticals’ Partner Acadia Gains FDA Approval for New Rett Syndrome Treatment
1M ago
Neuren Pharmaceuticals Faces Delay in FDA Meeting for NNZ-2591
Premium
Company Announcements
Neuren Pharmaceuticals Faces Delay in FDA Meeting for NNZ-2591
1M ago
Neuren Pharmaceuticals to Quote 150,000 New Securities on ASX
Premium
Company Announcements
Neuren Pharmaceuticals to Quote 150,000 New Securities on ASX
2M ago
More NURPF News >

NURPF News on the Web

Neuren Pharmaceuticals (ASX:NEU) Valuation Check After DAYBUE Growth Outlook And Pipeline Progress
Simply Wall St
Neutral
Scott Power: ASX healthcare stocks lift as sentiment improves
StockHead
Neutral
Inside Biotech: Neuren snaps back after rally — what’s priced in now?
Proactive Investors
Neutral
Neuren Pharmaceuticals flags DAYBUE global sales potential of US$700m by 2028
Proactive Investors
Neutral
Lunch Wrap: ASX drifts lower but oil prices keep energy stocks humming
StockHead
Neutral
The next 3 years could be huge for this ASX healthcare stock. Here's why
The Motley Fool
Neutral
Neuren’s Partner Acadia Sees DAYBUE Sales Climbing to US$700m by 2028
TipRanks News
Neutral
Which ASX 200 market sectors delivered the best dividend yields in 2025?
The Motley Fool
Neutral

News Score - Last 7 Days

Neutral
NURPF
Sector Average
Media Buzz
This Week7 articles
Weekly Average3 articles
News Sentiment
This Week50%
Sector Average57%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is NURPF’s Media Buzz Sentiment?
7 articles about NURPF were published this week. In an average week, 3 articles are published.
    What is NURPF’s weekly average amount of articles?
    In an average week, 3 articles about NURPF are published.
      What is NURPF’s News Sentiment?
      50% of articles about NURPF were positive this week, compared to its sector average of 57%.
        Healthcare Stocks that are Trending in the News
        CAHCardinal Health
        ALKSAlkermes
        WSTWest Pharmaceutical Services
        AGENAgenus
        PENPenumbra
        Showing the stocks with the most bullish news sentiment over the past week